TRADING DESK FINAL DECISION - ONE-PAGE EXECUTIVE SUMMARY

Date: December 7, 2025 | Portfolio: EUR 1,271.97 | Window: Dec 9-19, 2025

FINAL VERDICT: APPROVE WITH MAJOR MODIFICATIONS

ORIGINAL PROPOSAL: REJECTED

• PLTR 49.7% (REJECT - P/E 413 valuation bubble)
• IONQ 18.0% (REJECT - Beta 2.62, failed screening, gapping down)
• CRSP 23.3% (INCREASE to 61.6%)
• Expected Return: +2-3%, Risk: 4.5/5 (HIGH-EXTREME)

APPROVED PORTFOLIO: OPTION A (RECOMMENDED)

• CRSP 61.6% (16 shares at $56.88 = EUR 784)
• CASH 37.7% (EUR 480 FOMC buffer)
• FEES 0.6% (EUR 8)
• Expected Return: +9.5%, Risk: 3.5/5 (MODERATE-HIGH)

THE THREE-STOCK VERDICT

CRSP (CRISPR Therapeutics) - STRONG BUY

Decision: Increase from 23.3% to 61.6% Shares: 16 at $56.88 = $910 (EUR 784) Entry: $56-58 (Monday Dec 9 market open) Stop Loss: $52.00 (HARD STOP, -8.6% = -5.3% portfolio) Target 1: $65 (sell 50%, +14.3%) Target 2: $78 (sell remaining 50%, +37%) R/R Ratio: 3.0:1 (EXCELLENT)

Why STRONG BUY:

• ONLY stock with approved product (CASGEVY) generating revenue
• $1.9B cash runway (4.6 years) = fortress balance sheet
• Triple catalyst: 27.3% short interest + M&A rumors + CASGEVY acceleration
• Beta 1.73 manageable (vs IONQ 2.62)
• Cash floor $21/share = 37% downside cushion
• Multi-agent consensus: All teams APPROVE

Key Risks:

• Biotech binary outcomes (clinical trial failures)
• FOMC hawkish shock (40% probability)
• M&A rumors may not materialize (90% fail rate)

PLTR (Palantir Technologies) - STRONG AVOID

Decision: Reduce from 49.7% to 0% Alternative (if speculating): Maximum 15% (1 share = EUR 157)

Why REJECT:

• P/E 413 = 27.5x Graham's 15x maximum (catastrophic valuation)
• Zero margin of safety (Graham Number $5 vs Price $182 = -3,621% overvalued)
• FOMC hawkish risk (40% prob) = -8% to -15% drop
• Insider selling $180M+ in Q3 (smart money exiting)
• RSI 72 overbought (exhaustion risk)
• Risk/reward 0.34:1 (NEGATIVE)
• No catalysts in 10-day window (earnings Feb 2026)

Business Quality: A+ (47% revenue growth, $5.8B cash, 32% margin) Price Quality: F-- (unsustainable valuation bubble)

Graham's Verdict: "Beautiful company at terrible price. AVOID."

IONQ (IonQ Inc) - REJECT ENTIRELY

Decision: Reduce from 18% to 0%

Why REJECT:

• EXTREME risk rating (10/100 confidence - LOWEST possible)
• Beta 2.62 (FOMC hawkish = potential -15% single-day drop)
• Failed ALL screening filters (0.00/5.0 composite score)
• Gapping down -3.8% (momentum reversal signal)
• Pre-revenue quantum computing (no fundamentals)
• Distance to support -27.9% (no safety net)
• Risk/reward 0.6:1 (INVERSE - losing $31 to make $18)

Graham's Assessment: "Reckless speculation without fundamentals. Appalling."

TRADE EXECUTION PLAN

Monday, December 9 (Market Open)

1. BUY CRSP: 11 shares at $57.50 limit (max $58.50)
2. Set CRSP stop loss: $52.00 (GTC, hard stop)
3. Reserve 5 shares for dip entry ($54-55 if occurs Dec 9-10)
4. REJECT PLTR and IONQ (no positions)

Daily Monitoring (Dec 9-16)

• If CRSP hits $65: SELL 50% (8 shares), move stop to $58
• If CRSP flat/down: HOLD, monitor $52 stop
• Check Cathie Wood ARK trades daily (6:30 PM ET)

Pre-FOMC (December 16)

• If CRSP at $65+: HOLD 50%, ride through FOMC
• If CRSP at $54-58: SELL 50%, reduce FOMC exposure
• Result: Either 31% or 62% position into FOMC

FOMC Day (December 17)

• Dovish (60% prob): HOLD or add to winners
• Hawkish (40% prob): Stop loss may trigger at $52
• Post-FOMC: Reassess for Dec 18-19 finale

Final Exit (December 19 by 3:30 PM ET)

• SELL ALL remaining shares (MANDATORY)
• Target: $65-78 blended exit
• No exceptions (do NOT extend beyond 10 days)

RISK MANAGEMENT (7 CRITICAL RULES)

1. Stop Loss Discipline: $52 is HARD STOP (no discretion)
2. Position Size: Maximum 16 shares CRSP (no additions)
3. Time Discipline: ALL OUT by Dec 19 at 3:30 PM ET
4. Profit-Taking: Sell 50% at $65, 50% at $78 (no greed)
5. FOMC Risk: Reduce 50% on Dec 16 if flat/down
6. Emotional Control: Follow plan (no panic, no FOMO)
7. News Monitoring: Exit immediately if trial failure news

EXPECTED OUTCOMES

Base Case (50% probability): +8-12% portfolio

• CRSP exits at $65-68 blended average
• Profit: EUR 133 (+10.5% portfolio)

Bull Case (25% probability): +15-25% portfolio

• CRSP hits $78 (short squeeze or M&A)
• Profit: EUR 202 (+15.9% portfolio)

Moonshot (5% probability): +30-50% portfolio

• M&A bid at $85-100 announced
• Profit: EUR 457 (+36% portfolio)

Bear Case (15% probability): -5% to 0% portfolio

• Stop loss at $52 or breakeven exit
• Loss: EUR 67 (-5.3% portfolio) - ACCEPTABLE

Worst Case (5% probability): -10-15% portfolio

• Gap-down on trial failure (below $52 stop)
• Loss: EUR 164 (-12.9%) - FAILS 10% tolerance
• Mitigation: Monitor news, exit manually if pre-market bad news

Weighted Expected Value: +9.5% in 10 days (347% annualized)

FOMC RISK ASSESSMENT

Portfolio Beta: 1.07 (CRSP 61.6% × 1.73 + Cash 37.7% × 0)

Hawkish FOMC (40% prob):

• SPY -2.5%, CRSP -4.3% (beta impact)
• Position loss: -EUR 38 (-3.0% portfolio)
• Stop survives: $56.88 × -6% = $53.49 (above $52)

Dovish FOMC (60% prob):

• SPY +2%, CRSP +3.5% (beta impact)
• Position gain: +EUR 28 (+2.2% portfolio)

Expected FOMC Value: +0.12% (slightly positive)

Mitigation:

• 38% cash buffer absorbs shock
• Pre-FOMC reduction (sell 50% if flat)
• Stop loss caps downside at -5.3%

Verdict: MANAGEABLE (with pre-event position reduction)

SUCCESS CRITERIA

PASS (Minimum Acceptable):

• Portfolio return ≥ +5% (meets 5x SPY target)
• Maximum loss ≤ -10% (meets risk tolerance)
• Stop loss honored (discipline maintained)

SUCCESS (Target Outcome):

• Portfolio return +8-12% (base case)
• Sold 50% at $65 Target 1 (profit-taking)
• All risk rules followed (7/7 compliance)

EXCEPTIONAL:

• Portfolio return +15%+ (bull/moonshot case)
• M&A or full squeeze materialized
• Exited all by Dec 19 (time discipline)

FAIL:

• Portfolio loss > -10% (exceeded tolerance)
• Stop loss ignored (discipline failure)
• Extended past Dec 19 (time discipline failure)
• Emotional trading (panic/FOMO overrode plan)

GRAHAM'S FINAL WISDOM

"The investor's chief problem - and even his worst enemy - is likely to be himself."

• Benjamin Graham

This portfolio is SPECULATION, not investment.

Graham Would Approve:

• Rejecting extremes (PLTR P/E 413, IONQ beta 2.62)
• Concentrating on best idea (CRSP)
• Cash buffer (38% = margin of safety in liquidity)
• Stop loss discipline (protects capital)

Graham Would Criticize:

• 62% single stock (no diversification)
• 10-day horizon (not long-term investment)
• Catalyst dependence (squeeze/M&A rumors)
• 100% capital to speculation (should be 10% "mad money")

Graham's Verdict: "If you must speculate, speculate intelligently. This CRSP position has SOME fundamental basis (approved product, $1.9B cash). It is infinitely superior to IONQ (pre-revenue) or PLTR (P/E 413 bubble). But do NOT confuse a fortunate speculation with investment skill. Enforce your stops, take your profits, and EXIT by Dec 19."

FINAL RECOMMENDATION

APPROVE MODIFIED PORTFOLIO (Option A)

Condition for Approval: You MUST commit to ruthless discipline:

• Stop at $52? SELL (no excuses)
• Target at $65? SELL 50% (no greed)
• Dec 19 arrives? EXIT ALL (no extensions)

If you cannot commit to this discipline: → REJECT this portfolio → Reduce CRSP to 30-40% OR → Choose passive SPY investing instead

The portfolio will ONLY succeed if discipline matches analysis quality.

Signed: The Trading Desk Fund Manager December 7, 2025

"In Graham We Trust, In Discipline We Survive, In Risk Management We Prosper"

Full Analysis: /home/pengacau/pasar-malam/output/trading-desk-final-decision/ULTRA_AGGRESSIVE_PORTFOLIO_FINAL_DECISION_DEC7_2025.md